Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Cyclically Adjusted FCF per Share: ¥1.51 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
95 GF Score
Price ¥38.17
GF Value ¥40.76
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted FCF per Share?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 +1.95% 95 Cyclically Adjusted FCF per Share is ¥1.51 as of Mar. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 95/100 and a GF Value™ of ¥40.76 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Tibet Rhodiola Pharmaceutical Holding Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥1.184. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥1.51 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tibet Rhodiola Pharmaceutical Holding Co's average Cyclically Adjusted FCF Growth Rate was 21.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 35.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 35.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 108.00% per year. The lowest was -17.00% per year. And the median was 32.00% per year.

As of today (2026-07-29), Tibet Rhodiola Pharmaceutical Holding Co's current stock price is ¥38.17. Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥1.51. Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Price-to-FCF of today is 25.28.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Tibet Rhodiola Pharmaceutical Holding Co was 1158.52. The lowest was 23.58. And the median was 70.86.


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=38.17/1.51
=25.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Tibet Rhodiola Pharmaceutical Holding Co was 1158.52. The lowest was 23.58. And the median was 70.86.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted FCF per Share Related Terms


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted FCF per Share Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.56 0.76 1.13 1.40

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 1.31 1.32 1.40 1.51

SHSE:600211 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:600211
95GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tibet Rhodiola Pharmaceutical Holding Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.184/116.3033*116.3033
=1.184

Current CPI (Mar. 2026) = 116.3033.

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.043 101.400 0.049
201609 -2.484 102.400 -2.821
201612 3.232 102.600 3.664
201703 -0.032 103.200 -0.036
201706 -2.020 103.100 -2.279
201709 0.175 104.100 0.196
201712 0.163 104.500 0.181
201803 0.171 105.300 0.189
201806 0.179 104.900 0.198
201809 0.504 106.600 0.550
201812 -0.046 106.500 -0.050
201903 0.387 107.700 0.418
201906 0.911 107.700 0.984
201909 0.025 109.800 0.026
201912 0.411 111.200 0.430
202003 0.595 112.300 0.616
202006 0.015 110.400 0.016
202009 -0.097 111.700 -0.101
202012 0.224 111.500 0.234
202103 0.144 112.662 0.149
202106 -0.359 111.769 -0.374
202109 0.032 112.215 0.033
202112 -0.001 113.108 -0.001
202203 0.591 114.335 0.601
202206 0.671 114.558 0.681
202209 0.391 115.339 0.394
202212 0.625 115.116 0.631
202303 1.171 115.116 1.183
202306 0.477 114.558 0.484
202309 0.719 115.339 0.725
202312 0.857 114.781 0.868
202403 1.347 115.227 1.360
202406 0.463 114.781 0.469
202409 0.466 115.785 0.468
202412 0.690 114.893 0.698
202503 0.951 115.116 0.961
202506 0.882 114.907 0.893
202509 0.345 115.471 0.347
202512 0.889 115.832 0.893
202603 1.184 116.303 1.184

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥1.51 mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Cyclically Adjusted FCF per Share of ¥1.51 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted FCF per Share too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Cyclically Adjusted FCF per Share is ¥1.51. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted FCF per Share compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted FCF per Share of ¥1.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current Cyclically Adjusted FCF per Share is ¥1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.76, compared to a current price of ¥38.17 — trading 6.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥1.51. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Cyclically Adjusted FCF per Share is ¥1.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥38.17 is trading 6.4% below its estimated GF Value™ of ¥40.76. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Cyclically Adjusted FCF per Share: ¥1.51
  • GF Value™: ¥40.76 vs. price of ¥38.17 (6.4% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
95GF Score

Get the complete analysis for SHSE:600211

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.17
Price
¥40.76
GF Value